SynthesisFrontiers in oncology2026
Efficacy and safety of PD-1 inhibitors plus chemotherapy for advanced unresectable gastroesophageal cancer: a systematic review and meta-analysis of phase III randomized controlled trials.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The FDA approval of immune checkpoint inhibitors for advanced gastroesophageal cancer (GEC) independent of programmed death-ligand 1 (PD-L1) expression status has sparked notable clinical controversy, highlighting the urgent need for evidence-based evaluation of the efficacy and safety of various PD-1 inhibitors combinations for this malignancy. Methods: We followed the pre-registered PROSPERO protocol (CRD42022325401) to search the databases and conferences. The primary outcomes included overall survival (OS), progression-free survival (PFS), and treatment-related adverse event (TRAE). A random-effects model was applied for meta-analysis, with statistical data analysis performed using Review Manager software and the distribution of adverse event (AE) subtypes visualized via R software. Results: A total of 6625 patients from 9 phase III randomized controlled trials (RCTs) were ultimately included in this analysis. The overall risk of included RCTs was low. Results found immunotherapy combined with chemotherapy improved patients' prognosis more than single-agent chemotherapy, with corresponding increased but manageable adverse effects. Subgroup analyses by drug type further revealed that sintilimab in combination with chemotherapy exhibited more efficacy than other PD-1 inhibitor-based regimens. The survival benefit in the immunotherapy combined with chemotherapy group compared to chemotherapy alone was seen in both PD-L1 CPS positive and TPS positive. The evidence strength was moderate. Conclusion: Findings from this comprehensive study confirm that immunotherapy combined with chemotherapy is more efficacious than traditional chemotherapy in the first-line treatment of patients with advanced unresectable GEC. Sintilimab combined with chemotherapy demonstrated favorable efficacy and safety profiles compared with other PD-1 therapies in terms of OS and PFS benefit without increasing TRAE base on indirect comparisons. The moderate evidence indicated PD-1 combined with chemotherapy may be a viable option for advanced unresectable GEC. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022325401.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.